These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 1063129

  • 1. Immunological studies in murine osteosarcoma. Immunogenicity, growth kinetics, and immunotherapy.
    Miller CW, DeBlasi RF, Fisher SJ.
    J Bone Joint Surg Am; 1976 Apr; 58(3):312-7. PubMed ID: 1063129
    [Abstract] [Full Text] [Related]

  • 2. Immunotherapy with irradiated tumour cells and BCG in experimental osteosarcoma.
    Larsson SE, Lorentzon R, Boquist L.
    Acta Orthop Scand; 1981 Oct; 52(5):469-74. PubMed ID: 6949451
    [Abstract] [Full Text] [Related]

  • 3. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103+ conventional dendritic cells.
    Zhou Y, Slone N, Chrisikos TT, Kyrysyuk O, Babcock RL, Medik YB, Li HS, Kleinerman ES, Watowich SS.
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [Abstract] [Full Text] [Related]

  • 4. Tumor immunology of experimental osteosarcoma.
    Ghanta VK, Hiramoto RN, Weiss AB, Caudill L, Davis DW.
    Clin Orthop Relat Res; 1978 Jun; (133):246-60. PubMed ID: 278687
    [Abstract] [Full Text] [Related]

  • 5. BCG immunotherapy of rat tumors of defined immunogenicity.
    Baldwin RW, Pimm MV.
    Natl Cancer Inst Monogr; 1973 Dec; 39():11-9. PubMed ID: 4595312
    [No Abstract] [Full Text] [Related]

  • 6. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M, Itonaga I, Iwasaki T, Tsumura H.
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [Abstract] [Full Text] [Related]

  • 7. Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy.
    Morton DL, Eilber FR, Joseph WL, Wood WC, Trahan E, Ketcham AS.
    Ann Surg; 1970 Oct; 172(4):740-9. PubMed ID: 5272336
    [No Abstract] [Full Text] [Related]

  • 8. Prospects for tumor immunotherapy in man, with emphasis on its use as an adjunct to surgery for primary operable cancer.
    Southam CM.
    J Med Liban; 1975 Oct; 28(1):43-66. PubMed ID: 1107552
    [No Abstract] [Full Text] [Related]

  • 9. Effectiveness of neuraminidase in experimental immunotherapy of two murine pulmonary carcinomas.
    Alley CD, Snodgrass MJ.
    Cancer Res; 1977 Jan; 37(1):95-101. PubMed ID: 830425
    [Abstract] [Full Text] [Related]

  • 10. Suppression of transplanted rat sarcomata mediated by Bacillus Calmette Guéin (BCG).
    Moore M, Lawrence N, Witherow PJ.
    Eur J Cancer (1965); 1974 Oct; 10(10):673-82. PubMed ID: 4533899
    [No Abstract] [Full Text] [Related]

  • 11. Failure of Bacillus Calmette-Guérin (BCG) infection to suppress the growth of transplanted mouse and rat sarcomas.
    Símová J, Bubeník J.
    Folia Biol (Praha); 1973 Oct; 19(4):296-300. PubMed ID: 4356560
    [No Abstract] [Full Text] [Related]

  • 12. Comparative immunotherapeutic effect of concanavalin A and neuraminidase-treated cancer cells.
    Simmons RL, Rios A.
    Transplant Proc; 1975 Jun; 7(2):247-51. PubMed ID: 1129845
    [No Abstract] [Full Text] [Related]

  • 13. Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma.
    Udagawa T, Narumi K, Goto N, Aida K, Suzuki K, Ochiya T, Makimoto A, Yoshida T, Chikaraishi T, Aoki K.
    Hum Gene Ther; 2012 Feb; 23(2):173-86. PubMed ID: 21958207
    [Abstract] [Full Text] [Related]

  • 14. Effect of immunotherapy on the kinetics of proliferation of a transplanted rat rhabdomyosarcoma.
    Gia DT, Loisillier F.
    Eur J Cancer (1965); 1978 Oct; 14(10):1077-88. PubMed ID: 710477
    [No Abstract] [Full Text] [Related]

  • 15. Tumor regression and enhancement resulting from immunotherapy with Bacillus Calmette-Guérin and neuraminidase.
    Sparks FC, Breeding JH.
    Cancer Res; 1974 Dec; 34(12):3262-9. PubMed ID: 4471640
    [No Abstract] [Full Text] [Related]

  • 16. Immunogenicity of virus-induced rat osteosarcoma.
    Urovitz EP, Czitrom AA, Langer F, Gross AE, Pritzker PH.
    J Bone Joint Surg Am; 1976 Apr; 58(3):308-11. PubMed ID: 1063128
    [Abstract] [Full Text] [Related]

  • 17. Bacillus Calmette-Guérin contact immunotherapy of local and metastatic deposits of rat tumors.
    Baldwin RW, Hopper DG, Pimm MV.
    Ann N Y Acad Sci; 1976 Apr; 277(00):124-34. PubMed ID: 1069545
    [Abstract] [Full Text] [Related]

  • 18. Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas.
    Spence RJ, Simon RM, Baker AR.
    J Natl Cancer Inst; 1978 Feb; 60(2):451-9. PubMed ID: 621758
    [Abstract] [Full Text] [Related]

  • 19. Immuno-therapy of methyl cholanthrene induced and spontaneous tumors in mice by use of tumor vaccine, neuraminidase and BCG.
    Gautam S, Aikat BK.
    Indian J Med Res; 1976 Mar; 64(3):472-81. PubMed ID: 965048
    [No Abstract] [Full Text] [Related]

  • 20. Chemotherapy, BCG, and serum from tumor-bearing mice: comparative effects on growth and spread of mouse Lewis lung cancer.
    Greager JA, Culberson G, Manning B, Das Cupta TK.
    Arch Surg; 1975 Aug; 110(8):901-2. PubMed ID: 1156156
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.